Oscar Health, Inc.
Published Saturday, February 21, 2026
Executive Summary
Oscar Health is a high-growth ACA-focused health insurer that experienced a brutal 2025 — revenue grew 28% to $11.7B but the medical loss ratio spiked to 87.4% (from 81.7%), producing a net loss of $443M versus $25M net income in 2024. The stock is down 44% from its 52-week high and trades at roughly 0.35x revenue, a steep discount to health insurance peers. Management has guided for a sharp 2026 recovery with $18.7-19B revenue and $250-450M operating earnings, driven by aggressive repricing and continued membership growth (now ~3.4M members after adding 1M+ during open enrollment). The bull case is compelling on paper: Oscar is growing members at 2x the ACA market rate, its technology platform provides structural cost advantages, and 2026 repricing should restore margins. At 0.35x revenue, the stock prices in permanent impairment that seems unlikely given the membership trajectory. However, the bear case is real — the MLR spike reveals execution risk in managing medical costs at scale, the $443M loss demonstrates how quickly this business can swing negative, and ACA subsidy expiration remains an existential overhang. The company has never demonstrated sustained profitability. On balance, I lean cautiously bullish. The valuation is genuinely cheap for a business growing revenue 28% YoY with a clear path to profitability through repricing. The 2026 guidance, if even partially achieved, implies the stock is significantly undervalued. But execution risk is high and the path is not guaranteed — this is a show-me story where the market is right to demand proof before re-rating.
Price Targets
$17.00+28.5%
$25.00+89.0%
1-Year scenario price targets · Dashed line = current price
Scenario Analysis
| Scenario | 1Y Target | 1Y Growth | 3Y Target | 3Y Growth |
|---|---|---|---|---|
↑↑Hyper Bull | $25.00 | +89.0% | $45.00 | +240.1% |
↑Bull | $19.00 | +43.6% | $30.00 | +126.8% |
→Neutral | $14.00 | +5.8% | $18.00 | +36.1% |
↓Bear | $9.00 | -32.0% | $7.00 | -47.1% |
↓↓Hyper Bear | $5.00 | -62.2% | $3.00 | -77.3% |
Key Financial Metrics
- Earnings Per Share (EPS)
- N/A (unprofitable)
- Revenue
- $11.7B (2025), guided $18.7-19B (2026)
- P/E Ratio
- N/A (net loss of $443M in 2025)
- P/S Ratio
- ~0.35x (based on $11.7B 2025 revenue)
- Market Cap
- $4.09B
- Net Income
- -$443M (2025)
- Short Interest
- N/A (data not available)
- 52-Week Low
- $11.20
- 52-Week High
- $23.80
Technical Overview
44.2
bearish
1-Year daily closing prices
Micro Analysis
Oscar Health showed explosive membership and revenue growth in 2025 but suffered a dramatic profitability reversal. The key question is whether 2026 repricing can restore margins while maintaining growth momentum.
Explosive Membership Growth
Members grew from ~1.68M to ~2.04M during 2025, and open enrollment added another 1M+ bringing total to ~3.4M for 2026. This represents roughly 2x the overall ACA market growth rate of 13%, demonstrating Oscar's competitive advantage in member acquisition through its technology platform and user experience.
Medical Loss Ratio Deterioration
MLR spiked to 87.4% in 2025 from 81.7% in 2024, with Q4 reaching as high as 91.1%. This was driven by higher-than-expected market morbidity and utilization that risk adjustments did not fully offset. This 570bps deterioration turned a profitable company into one losing $443M, highlighting the razor-thin margin for error in health insurance.
2026 Guidance Implies Sharp Turnaround
Management guided for $18.7-19B revenue (60-62% growth) and $250-450M operating earnings in 2026. This implies a dramatic swing from -$396M operating loss to potentially +$450M operating income, predicated on aggressive premium repricing and continued membership growth. The wide range ($200M spread) reflects genuine uncertainty.
Technology Platform as Structural Advantage
Oscar's SG&A expense ratio improved to 17.5% despite absolute cost increases, suggesting the tech platform delivers real operating leverage. The Oswell AI chatbot and full-stack technology differentiate Oscar from legacy insurers and should enable better unit economics at scale. However, the MLR spike shows technology alone cannot solve medical cost management.
Balance Sheet and Liquidity
Oscar secured a $475M credit facility, providing liquidity runway through the 2026 recovery period. However, with a $443M net loss in 2025, cash burn is significant and the company needs to demonstrate it can achieve profitability before requiring additional capital. The market cap of ~$4B against $11.7B revenue gives a P/S of ~0.35x, well below peer average of ~3.19x.
Macro Analysis
The ACA marketplace continues to grow but faces significant policy uncertainty around subsidy expiration. The broader healthcare cost environment remains inflationary, creating both pricing power opportunities and margin risk.
ACA Subsidy Expiration Risk
Enhanced ACA subsidies are set to expire, which could reduce enrollment in marketplace plans. Oscar's entire business model depends on ACA exchanges. If subsidies expire without renewal, membership could decline materially as plans become unaffordable for lower-income enrollees. Piper Sandler notes Oscar has designed 2026 products to perform even in adverse subsidy scenarios, but this remains the single largest macro risk.
Healthcare Cost Inflation
Industry-wide medical cost trends accelerated in 2025, catching most insurers off-guard. Higher utilization rates and market morbidity drove MLR increases across the sector (CVS also reported diverging results). While 2026 repricing should partially address this, persistent healthcare inflation could continue to pressure margins even after rate increases.
Regulatory and Political Environment
The ACA marketplace is inherently political. Changes in administration priorities, Medicaid redetermination effects, and potential regulatory shifts could impact Oscar's addressable market. The company's concentration in ACA individual/family plans makes it uniquely exposed to policy changes compared to diversified insurers.
Interest Rate Environment
With 10-year Treasury rates around 4.14%, the cost of capital remains elevated. Oscar's $475M credit facility provides near-term liquidity, but if the company needs to raise equity capital, dilution at current depressed prices would be painful for shareholders. Higher rates also increase the discount rate applied to Oscar's future earnings, pressuring valuation multiples.
Competitive Landscape Intensifying
Legacy insurers like UnitedHealth, Centene, and Molina are investing more heavily in ACA exchanges. The loss of the Cigna+Oscar small-group partnership at end of 2024 removes a growth channel. As the ACA market matures, customer acquisition costs could rise and Oscar's growth premium could erode.
Untapped Revenue Opportunities
2026 Premium Repricing
highOscar is implementing significant premium increases for 2026 to offset the higher medical costs experienced in 2025. With 3.4M members and guided revenue of $18.7-19B (up from $11.7B), the repricing should restore margins while the larger member base provides operating leverage on fixed costs.
Geographic and Market Expansion
highOscar plans to expand into 150 new metros by 2027. The company currently operates in 18 states, and each new market represents incremental membership and revenue. The technology platform allows relatively capital-light market entry compared to legacy insurers building physical infrastructure.
Technology Platform Licensing (Oscar+)
mediumOscar's full-stack technology platform could be licensed to other insurers and providers, creating a capital-light, high-margin revenue stream. This would diversify revenue beyond insurance underwriting and could command SaaS-like multiples if scaled successfully.
AI-Driven Cost Reduction
mediumThe Oswell AI chatbot and broader AI capabilities could reduce administrative costs, improve claims management, and enhance member engagement. If AI can help identify high-cost members earlier and direct them to more cost-effective care pathways, it could structurally improve the MLR over time.
Headwinds & Tailwinds
↓ Headwinds
ACA Subsidy Expiration
highIf enhanced ACA subsidies expire without renewal, Oscar could lose a significant portion of its member base as plans become unaffordable. This is an existential risk for a company 100% dependent on ACA exchanges. Even partial subsidy reduction could meaningfully impact enrollment and revenue growth.
Medical Cost Volatility and MLR Risk
highThe 2025 MLR spike to 87.4% demonstrates that Oscar's ability to predict and manage medical costs at scale is unproven. Even with repricing, unexpected utilization spikes or new cost pressures (e.g., GLP-1 drugs, behavioral health) could again push MLR above sustainable levels. The company has never demonstrated consistent profitability.
Execution Risk on Rapid Scaling
mediumAdding 1M+ members in a single enrollment period creates enormous operational strain. Provider network adequacy, claims processing capacity, and customer service quality could all suffer. Rapid growth in insurance often leads to adverse selection if underwriting discipline slips.
Loss of Cigna+Oscar Partnership
mediumThe end of the Cigna+Oscar small-group partnership at year-end 2024 removes a meaningful growth channel and revenue diversification opportunity. Oscar is now more concentrated in individual/family ACA plans, increasing its policy risk exposure.
Negative Momentum and Sentiment
mediumThe stock is down 44% from its 52-week high with deteriorating momentum scores. Monthly decline of 19%+ and unfavorable price trends across all timeframes suggest institutional selling. RSI at 44.2 is not yet oversold, meaning further downside is possible before a technical bottom forms.
↑ Tailwinds
Extreme Valuation Discount
highAt ~0.35x revenue, Oscar trades at roughly 1/9th the peer average of ~3.19x revenue. Even applying a significant discount for profitability uncertainty, the current valuation implies the market expects permanent value destruction. If Oscar achieves even modest profitability, significant re-rating is likely.
Membership Growth Momentum
highGrowing from 200K members in 2019 to 3.4M in 2026 demonstrates product-market fit and competitive advantage. The 2x ACA market growth rate suggests Oscar is taking share from incumbents, not just riding market expansion. This growth provides operating leverage and bargaining power with providers.
Technology-Driven Operating Leverage
mediumSG&A ratio improvement to 17.5% demonstrates that Oscar's technology platform delivers real cost advantages at scale. As membership grows, fixed technology costs are spread across more members, structurally improving unit economics. This is a genuine moat that legacy insurers cannot easily replicate.
Piper Sandler Upgrade and Institutional Interest
mediumPiper Sandler upgraded OSCR to buy with a $25 price target, nearly 2x the current price. While Wall Street consensus skews bullish, the specific thesis — that Oscar can gain share even if ACA subsidies expire — provides a differentiated bull case. The 35% weekly pop on the upgrade shows latent demand for the stock.
Analysis Summary
- Ticker
- OSCR
- Company
- Oscar Health, Inc.
- Analysis Date
- 2026-02-21
- Price at Analysis
- $13.23
- Rating
- Buy
- 1Y Price Target
- $17.00
- 3Y Price Target
- $25.00
- Market Cap
- $4.09B
- P/E Ratio
- N/A (net loss of $443M in 2025)
This analysis was generated on 2026-02-21 when OSCR was trading at $13.23. The base-case 1-year price target is $17.00 (+28.5% implied return). Scenario range: $5.00 (hyper bear) to $25.00 (hyper bull).